While medications like Wegovy and Zepbound have revolutionized obesity care, the barrier of weekly needles has remained a challenge for many patients
Combining glucagon-like peptide 1 receptor agonists and sodiumglucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes
Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist
The Future of GLP-1 Treatments We understand that obesity and other metabolic conditions are systematic issues stemming from flaws in our healthcare systems, the food industry, and lifestyle choices
These are prescription medications that affect metabolic processes
Este hito sigue al lanzamiento, en junio de 2024, del primer GLP-1 genrico para diabetes tipo 2, tambin desarrollado por Teva, equivalente a liraglutida 1,8 mg (Victoza)